Clinical Trial Update: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting results from a Phase 1/2 study of a conditioning regimen using gemcitabine hydrochloride, clofarabine, and busulfan before donor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Clolar (Clofarabine)
• Gemzar (gemcitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-28